Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Oasmia Pharmaceutical AB (OASMY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.024x
Based on the latest financial reports, Oasmia Pharmaceutical AB (OASMY) has a cash flow conversion efficiency ratio of -0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.14 Million) by net assets ($133.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oasmia Pharmaceutical AB - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Oasmia Pharmaceutical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oasmia Pharmaceutical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oasmia Pharmaceutical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Matvareexpressen As
OL:MVE
|
0.213x |
|
AIM5 Ventures Inc
V:AIME-P
|
-0.143x |
|
GRENKELEASING
BE:GLJ
|
-0.069x |
|
BROTHER IND (BI5.SG)
STU:BI5
|
0.055x |
|
LUMINE GROUP (SUB.VTG.)
F:Z76
|
N/A |
|
BANK OF GREECE - Dusseldorf Stock Exchang
DU:BGC
|
N/A |
|
STRAX AB SK -03125
F:NOBC
|
N/A |
|
ARETTO WELLNESS INC.
F:0RW0
|
N/A |
Annual Cash Flow Conversion Efficiency for Oasmia Pharmaceutical AB (2004–2024)
The table below shows the annual cash flow conversion efficiency of Oasmia Pharmaceutical AB from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $158.33 Million | $-47.25 Million | -0.298x | +14.14% |
| 2023-12-31 | $197.80 Million | $-68.74 Million | -0.348x | -40.46% |
| 2022-12-31 | $325.42 Million | $-80.52 Million | -0.247x | +6.56% |
| 2021-12-31 | $549.71 Million | $-145.56 Million | -0.265x | +11.23% |
| 2020-12-31 | $686.74 Million | $-204.86 Million | -0.298x | -3460.04% |
| 2019-12-31 | $819.39 Million | $-6.87 Million | -0.008x | +97.01% |
| 2018-12-31 | $424.05 Million | $-118.84 Million | -0.280x | +21.79% |
| 2017-12-31 | $345.04 Million | $-123.63 Million | -0.358x | +19.08% |
| 2016-12-31 | $300.37 Million | $-133.01 Million | -0.443x | -12.69% |
| 2015-12-31 | $326.05 Million | $-128.13 Million | -0.393x | -37.13% |
| 2014-12-31 | $375.71 Million | $-107.67 Million | -0.287x | +7.04% |
| 2013-12-31 | $281.91 Million | $-86.90 Million | -0.308x | -41.47% |
| 2012-12-31 | $319.15 Million | $-69.54 Million | -0.218x | -13.63% |
| 2011-12-31 | $273.47 Million | $-52.44 Million | -0.192x | +2.07% |
| 2010-12-31 | $294.17 Million | $-57.60 Million | -0.196x | -147.13% |
| 2009-12-31 | $141.80 Million | $-11.23 Million | -0.079x | -133.97% |
| 2008-12-31 | $61.21 Million | $14.28 Million | 0.233x | +167864.83% |
| 2007-12-31 | $64.81 Million | $9.00K | 0.000x | +100.07% |
| 2006-12-31 | $110.30 Million | $-22.73 Million | -0.206x | -7.71% |
| 2005-12-31 | $58.90 Million | $-11.27 Million | -0.191x | -192.02% |
| 2004-12-31 | $31.40 Million | $6.53 Million | 0.208x | -- |